Abeona Therapeutics (NASDAQ:ABEO) Stock: Insider Brendan O’malley Sells 6,727 Shares

Posted by Stanley Muller on Sep 29th, 2026

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) SVP Brendan O’malley sold 6,727 shares of the company’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total value of $34,711.32. Following the transaction, the senior vice president directly owned 421,226 shares in the company, valued at $2,173,526.16. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abeona Therapeutics Stock Down 2.5%

Abeona Therapeutics stock traded down $0.13 during mid-day trading on Tuesday, hitting $5.16. The company’s stock had a trading volume of 1,253,359 shares, compared to its average volume of 1,359,931. Abeona Therapeutics Inc. has a 52-week low of $4.00 and a 52-week high of $7.65. The company has a market cap of $295.07 million, a PE ratio of -4.73 and a beta of 1.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.40. The firm’s 50 day moving average is $6.07 and its 200 day moving average is $5.72.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The firm had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million. On average, analysts anticipate that Abeona Therapeutics Inc. will post -0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

ABEO has been the subject of a number of research reports. Weiss Ratings lowered shares of Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 17th. Cantor Fitzgerald increased their price objective on Abeona Therapeutics from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, September 18th. UBS Group reissued a “buy” rating on shares of Abeona Therapeutics in a research report on Friday. Oppenheimer restated an “outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Abeona Therapeutics in a research note on Friday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Abeona Therapeutics in a research report on Friday. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Abeona Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Get Our Latest Research Report on ABEO

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. AWM Investment Company Inc. acquired a new stake in Abeona Therapeutics in the 2nd quarter worth $9,184,000. AIGH Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 55.0% in the first quarter. AIGH Capital Management LLC now owns 3,100,000 shares of the biopharmaceutical company’s stock valued at $13,888,000 after buying an additional 1,100,000 shares during the period. Bank of New York Mellon Corp acquired a new stake in Abeona Therapeutics during the second quarter worth about $1,262,000. Sei Investments Co. grew its position in Abeona Therapeutics by 142.4% during the first quarter. Sei Investments Co. now owns 172,460 shares of the biopharmaceutical company’s stock worth $773,000 after buying an additional 101,307 shares in the last quarter. Finally, Corient Private Wealth LP bought a new position in Abeona Therapeutics during the second quarter valued at about $556,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing cell and gene therapies for patients with serious and life-threatening genetic diseases. The company’s programs are designed to address conditions for which existing treatment options are limited or inadequate.

Abeona’s lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and chronic wounds.